A growing number of patients survive sepsis but remain chronically critically ill. We sought to define clinical outcomes and incidence of chronic critical illness (CCI) after sepsis and to determine whether selected biomarkers of inflammation, immunosuppression, and catabolism differ between these patients and those that rapidly recover (RAP).
S
epsis is a major source of morbidity and mortality. 1, 2 Over the past decade, in-hospital mortality after sepsis has progressively declined secondary to advances in the early recognition of sepsis and prompt intervention based on evidenced-based guidelines. 3, 4 Despite these improvements, sepsis remains a morbid disease with poor long-term outcomes including lasting physical, cognitive, and psychiatric deficits, as well as high rates of postdischarge mortality. 5, 6 Additionally, at a biologic level, sepsis is now evolving into a chronic inflammatory disease. We have observed that while an increasing number of surgical intensive care unit (ICU) (SICU) patients survive their acute illness and recover from multiple organ failure (MOF), they commonly remain hospitalized for extended periods with complicated clinical courses and evidence of persistent inflammation, immunosuppression, and protein catabolism. 7, 8 Several descriptive terms have been used by investigators to convey the chronicity of adverse outcomes which are observed in these patients. These terms include, but are not limited to, "chronic critical illness," "postintensive care syndrome," "myopathy of critical illness," "neuropathy of critical illness," and "ICU-acquired weakness." [9] [10] [11] [12] For the purpose of this study, we will refer to the lasting sequelae after sepsis as chronic critical illness (CCI). At present, there is no well accepted and widely used definition for CCI among the scientific and medical communities, which makes defining its epidemiology difficult. Despite the variance among definitions of CCI, they usually agree in two components: (1) the requirement for prolonged intensive care and (2) presence of persistent organ dysfunction. Therefore, we aimed to determine the incidence of CCI in surgical patients after sepsis using a set of standardized criteria based on prolonged intensive care resource utilization and persistent, low-grade organ dysfunction.
In addition to benchmarking the epidemiology of CCI, we sought to identify evidence for unifying mechanistic explanation for CCI. We have proposed that adverse outcomes observed in sepsis survivors in the SICU are linked with a syndrome of persistent inflammation, immunosuppression, and catabolism (PICS). 7, 8, 13, 14 In previous work, we showed that severely injured trauma patients who experience complicated clinical outcomes demonstrate persistent alterations in proinflammatory and anti-inflammatory cytokines, leukocyte subsets, and biomarkers of protein catabolism. 15 Similarly, we hypothesize that patients who develop CCI after sepsis will exhibit lasting derangements in biomarkers of inflammation, immunosuppression, and protein catabolism as compared with patients who exhibit recovery.
METHODS

Study Design, Site, and Patients
This prospective observational study was conducted between January 2012 and January 2016 at an academic, 996-bed quaternary medical center. Overall program study design and protocols for the Sepsis and Critical Illness Center research program have been published. 16 Additional methodologic details to those described below are available in Supplemental Digital Content 1 (http://links.lww.com/TA/B50). The study received institutional review board approval before initiation. Signed informed consent from the patient or legal proxy was obtained within 96 hours of study enrollment. Patients included in this study were admitted to the SICU and either admitted with, or subsequently developed sepsis. Sepsis screening was performed using the Modified Early Warning Signs-Sepsis Recognition System. 17 All enrolled patients were managed using a standardized sepsis management protocol based on the Surviving Sepsis guidelines, supplemented by standardized evidencedbased ICU clinical care protocols and utilization of a computerized clinical decision support system to ensure high compliance and timely intervention. 17, 18 Patient Enrollment, Classification, and Outcomes Inclusion criteria consisted of the following: (1) age ≥18 years; (2) presence in the SICU; and (3) clinical diagnosis of sepsis, severe sepsis, or septic shock as defined by the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. 19 Sepsis diagnoses were clinically adjudicated in a prospective fashion at weekly program adjudication meetings.
Exclusion criteria consisted of the following: (1) refractory shock (death <24 hours) or inability to achieve source control (e.g., unresectable dead bowel); (2) presepsis expected lifespan <3 months; (3) patient goals of care not consistent with aggressive management; (4) severe CHF (NYHA class IV); (5) ChildPugh Class C liver disease or preliver transplant; (6) HIV with
CD4
+ count less than 200 cells/mm 3 ; (7) chronic corticosteroids or immunosuppressive agent use, including organ transplant recipients; (8) pregnancy; (9) chemotherapy or radiotherapy within past 30 days; (10) severe traumatic brain injury (evidence of neurologic injury on CT scan and GCS <8); or, (11) spinal cord injury resulting in permanent sensory and/or motor deficits.
The CCI was defined as an ICU length of stay (LOS) greater than or equal to 14 days with evidence of persistent organ dysfunction, determined using components of the Sequential Organ Failure Assessment (SOFA) score (cardiovascular SOFA, ≥ ;, or score in any other organ system, ≥ 2). 20 Therefore, a wide representation of organ dysfunction was incorporated, including patients with respiratory, cardiovascular, neurologic, coagulative, liver, and renal dysfunction. Rapid recovery (RAP) patients were those who did not meet criteria for CCI or early death (death <14 days of sepsis protocol onset). Primary outcomes included in-hospital mortality, hospital and ICU LOS, ventilator days, presence and severity of organ dysfunction, acute respiratory distress syndrome, acute kidney injury (AKI), development of CCI, and discharge disposition. Six-month mortality was determined by prospective follow-up, with cross-check validation via the United States Social Security Death Index.
Laboratory Analyses
Blood samples were collected and analyzed for biomarkers of inflammation (IL-6, IL-8, IL-10), immunosuppression (absolute lymphocyte count and soluble programmed death ligand 1 [sPDL-1]), and catabolism (insulin-like growth factor binding protein 3 [IGFBP3]) at 12 hours, 1 day, 4 days, 7 days, and 14 days, and weekly thereafter while hospitalized. Urine was collected for measurement of 3-methylhistidine (3-MH) to creatinine ratios at similar time frames. 21 
Statistical Analysis
Data are presented as either frequency and percentage, or mean and standard deviation, or median and 25th/75th percentiles. Student's t test, analysis of variance, and Kruskal-Wallis tests were used for comparison of continuous variables as appropriate. Measured biomarkers were compared using nonparametric rank tests to determine significant differences between groups at each time point. Mixed model analysis was also performed to determine differences between groups over time.
Two multivariate logistic regression models at 24 hours and 72 hours after sepsis onset were constructed by a stepwise model selection at a significance level of 0.10. Adjusted odds ratios (OR) with 95% confidence intervals (95% CI) and the area under the receiver operating characteristics curve values and Hosmer-Lemeshow goodness-of-fit test were used. All significance tests were two-sided, with p value of 0.05 or less considered statistically significant. Statistical analyses were performed with SAS (v.9.4, Cary, NC).
RESULTS
Of the 145 study patients, 29 (20%) were diagnosed with sepsis, 56 (39%) with severe sepsis, and 60 (41%) with septic shock. Mean age was 61 ± 14 (SD) years with a slight predominance of male patients (n = 82, 56%). Seventy-one percent of the patients (n = 103) had at least one medical comorbidity, while almost half (n = 57, 45%) had two or more comorbidities. Sixty-one (42%) patients were transfers from another acute care facility at the time of index admission. There was a broad range of sepsis severity, with increasing APACHE II scores proportionate to sepsis severity (sepsis, mean 14 ± 6; severe sepsis, mean 21 ± 7; septic shock, mean 25 ± 8). Detailed cohort characteristics are listed in Supplemental Digital Content 2 (http:// links.lww.com/TA/B50).
The primary source of sepsis was intra-abdominal infection, followed by pneumonia, necrotizing soft tissue infection, urinary tract infection, surgical site infection, and central lineassociated bloodstream infection (Supplemental Digital Content 3, http://links.lww.com/TA/B50). More than half (55%) of patients required a surgical or interventional procedure for source control. Although most patients (62%) had sepsis "present on admission" (diagnosed within 48 hours), 38% of patients were diagnosed with "delayed onset" sepsis (sepsis occurring >48 hours after hospital admission secondary to a postsurgical or posttraumatic injury infection), with a median onset of eight days. The most common causes of delayed onset sepsis included postoperative bowel perforation/anastomotic leaks, ventilatorassociated pneumonia, and urinary tract infections. Subgroup analysis of sepsis, severe sepsis, and septic shock revealed that septic shock patients were older (sepsis, 58 ± 13 years; severe sepsis, 58 ± 15 years; septic shock, 65 ± 14 years; p = 0.01), but there were no significant differences found in race, sex, BMI or number of comorbidities. However, the incidence of AKI increased with sepsis severity (sepsis, 38%; severe sepsis, 54%; septic shock, 77%; p = 0.0002).
Clinical Outcomes and the Incidence of CCI
Overall in-hospital mortality for this sepsis cohort was 13%. As expected, those with septic shock exhibited the highest mortality rates (sepsis, 3%; severe sepsis, 5%; septic shock, 25%; p = 0.003), longest ICU LOS (median days: sepsis, 4; severe sepsis, 12; septic shock, 12; p < 0.0001), and the greatest number of ventilator days (median days: sepsis, 4; severe sepsis, 7; septic shock, 10; p = 0.01).
Clinical trajectories after sepsis and their patient characteristics are shown in Table 1 . The eight patients experiencing 'early death' (median, 6 days) were older, had more severe organ dysfunction within the first 24 hours, and presented with an early overwhelming response to infection as indicated by a higher frequency of septic shock (Table 1) . Roughly half (n = 71, 49%) of all septic patients developed CCI (Table 1) . In comparison to patients with RAP, CCI patients were older, exhibited greater sepsis severity and early physiologic derangement, and were more likely to have been admitted as an interfacility hospital transfer (Table 1 ). There were no significant differences between the groups in number of comorbidities, need for sepsis source control procedure, or infection type. Clinical outcomes clearly differed among the CCI and RAP groups (Table 2) . CCI patients had significantly higher maximum SOFA scores and a greater rate of MOF than RAP patients. Additionally, CCI patients had both higher incidence and severity of AKI. Hospital LOS for CCI patients was almost three times as long as that for RAP patients. Ultimately, 80% of patients who developed CCI had a "poor" hospital discharge disposition. Of CCI patients who survived to discharge, nearly two thirds required placement in either a long-term acute care facility, skilled nursing facility, another inpatient hospital, or hospice. In contrast, over 70% of RAP patients were discharged to home or to a rehabilitation facility ( Table 2 ). In addition to requiring higher levels of care upon discharge, CCI patients demonstrated significantly increased postdischarge mortality, with over one-third (37%) of CCI patients dying within the first 6 months of sepsis diagnosis, as compared with 2% in the RAP group (p < 0.01) (Fig. 1) .
We developed two multivariate risk factor models in order to facilitate prediction of CCI based on readily available clinical data at 24 hours and 72 hours after sepsis diagnosis (Table 3) . At 24 hours, delayed onset of sepsis, interfacility transfer at admission, and vasopressor-dependent septic shock were identified as independent predictors of development of CCI. Persistent multiple organ dysfunction at 72 hours from sepsis onset was also an independent predictor of CCI, but did not significantly improve risk factor model prediction (Table 3) .
CCI and Persistent Inflammation, Immunosuppression, and Catabolism
There were significant differences in biomarkers of inflammation, immunosuppression, and catabolism between CCI and RAP patients. Patients who developed CCI demonstrated a more robust early inflammatory response, with pronounced Adjusted ORs were derived using the multivariable logistic regression that included all listed variables in the model simultaneously. Baseline (24 hours) model included age, sex, Charlson comorbidity score, delayed sepsis, interfacility transfer, septic shock status, and dichotomized SOFA scores where cut-off was calculated by maximizing sensitivity and specificity along the receiver operating characteristic curves. Final reduced set of variables were selected by a stepwise model selection at a significance level of 0. 10. and sustained elevations in plasma IL-6, IL-8, and IL-10 out to 28 days (Fig. 2) . These patients also demonstrated a significantly greater initial degree, and persistence of immune suppression as reflected by measured sPDL-1 levels (Fig. 2) . Furthermore, absolute lymphocyte counts in CCI patients remained suppressed and significantly decreased (Fig. 2) . Finally, there were significant differences between groups in markers of catabolism, as measured by urine 3-methylhistidine to creatinine ratio and plasma IGFBP3 levels (Fig. 2) .
DISCUSSION
Although inpatient mortality to sepsis has recently declined due to implementation of evidence based care, this success is paralleled by an emerging epidemic of CCI. Although Figure 2 . Biomarker concentrations for inflammation, immunosuppression and protein catabolism in patients with CCI and RAP. Blood and urine samples were collected at 0.5 days, 1 days, 4 days, 7 days, 14 days, 21 days, and 28 days after sepsis management protocol onset. Plasma concentrations of IL-6, IL-8, and IL-10 were used to assess the inflammatory status of the subject (panel A), plasma sPDL-1 and absolute lymphocyte count to assess immune suppression (panel B), and urinary 3-methylhistidine excretion normalized to creatinine excretion and plasma IGFBP3 concentrations were used as markers of protein catabolism (panel C). Complete cases for laboratory results were binned to the closest time point. Differences in concentrations between CCI (filled circles) and RAP (filled triangles) cohorts at individual time points are identified with an asterisk at a p value less than 0.05 using nonparametric tests. The results of mixed model analyses reveal that the levels of all analytes over time were significantly different between groups (p < 0.05). Patients with CCI had significantly increased early and late inflammation, as well as prolonged immune suppression and evidence of increased muscle protein catabolism (3-MH) and reduced anabolic signals (IGFBP3). *p < 0.05 at that time point; shaded areas are normal ranges.
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Volume 84, Number 2 variably defined, CCI is consistently linked to poor long-term outcomes and high health care expenditures. 22, 23 In this prospective observational study, we document the incidence of CCI in 145 critically ill patients who developed sepsis, using a definition based on our previous work. 24, 25 We found that CCI is not only prevalent within the SICU, but represents the predominant clinical trajectory in patients who survive sepsis. Of the entire cohort, 87% survived their initial septic insult; however, 52% of these surviving patients progressed to a state of CCI. These patients, by definition, had persistent, low-grade organ dysfunction, and were more likely to be discharged to long-term acute care facilities, skilled nursing facilities, other hospitals, and hospice in comparison to those with rapid recovery (RAP). These findings have significant long-term implications, since one third of patients discharged to skilled nursing facilities never return home, and nearly another third (29%) are dead at 1 year. 26 To develop therapeutic interventions aimed at preventing progression to CCI after sepsis, early identification of those likely to progress to CCI will be essential. Here we show that independent risk factors for the development of CCI can be determined within 24 hours of sepsis onset and include delayed onset of sepsis, vasopressor-dependent septic shock, transfer from another hospital, and persistent organ dysfunction. Delayed onset sepsis (i.e., hospital-acquired sepsis) was by far the strongest independent predictor of CCI and was frequently observed in patients who were initially admitted for a planned surgical procedure or following severe traumatic injury. This suggests that recurrent inflammatory insults may redirect a patient's trajectory to that of CCI and PICS. Aside from this "second-hit" hypothesis, another possibility is that patients with delayed onset sepsis acquire more resistant and difficult to treat pathogens in the hospital, as opposed to patients who were admitted from the community with sepsis. Vasopressor-dependent septic shock and hospital transfer status were anticipated risk factors for CCI, suggesting greater physiologic derangement or possible delays in sepsis treatment. With further refinement and subsequent analyses, including addition of the biomarkers and future validation studies, it may be possible to identify the cohort of CCI patients who may potentially benefit from interventions such as targeted immunomodulation with emerging, novel agents.
In previous studies, we showed that evidence of the PICS is found in trauma patients who experience complicated clinical outcomes. 7, 15 In this study, we now demonstrate that this biologic phenotype is also present in CCI patients following sepsis. Compared with patients who rapidly recover, CCI biomarker profiles indicate a more robust and persistent inflammatory response that lasts at least four weeks after sepsis onset. Simultaneously, these patients exhibit polarization of innate inflammatory responses over adaptive immunity with indirect evidence of adaptive immune suppression, including reduced absolute lymphocyte counts and elevated sPDL-1 concentrations. This has clinical implications since previous studies in sepsis patients demonstrate that lower absolute lymphocyte counts are linked to reactivation of latent viral infections 27 and place patients at increased risk for recurrent bacterial infections. 28 Persistently elevated levels of the antiinflammatory cytokine, IL-10, in the CCI group, may also reflect the hosts attempt to down-regulate the inflammatory response in order to limit ongoing immune-mediated damage.
Therefore, increased levels of IL-10 may also serve as a surrogate of immune suppression.
In addition to immunosuppression, CCI patients demonstrate evidence of increased protein catabolism given their elevated mean urinary 3-MH to creatinine excretion ratios and lower levels of IGFBP3, which is a carrier protein of insulinlike growth factor. We chose this as a marker of catabolism since suppression of the somatotropic axis is linked to critical illness. [29] [30] [31] Taken together, this constellation of findings is supportive of the presence of PICS in patients with CCI, affords an underlying mechanistic explanation, and suggests potential areas of future targeted therapies.
The underlying mechanisms of dysfunctional inflammation and immunosuppression in these patients remain unclear. However, we recently reported that a population of immature myeloid cells, termed myeloid-derived suppressor cells (MDSCs), are persistently elevated in the blood of septic patients. Importantly, MDSCs suppress T lymphocyte proliferation and decrease the release of T h1 and T h2 cytokines. Exaggerated MDSC expansion correlated with early mortality and persistent MDSC expansion was a strong independent predictor of nosocomial infections and poor discharge dispositions. 13 Interestingly, the increases in MDSCs seen in postsepsis patients are remarkably similar to those seen in advanced cancer. 32, 33 These similarities provide a rationale for using therapies successful in reversing T-cell immunosuppression in patients with sepsis. As an example, Bristol-Myers-Squibb has recently initiated a clinical trial with nivolumab (Opdiva, a monoclonal antibody against PD-1) in septic patients (NCT:CA209-923).
This study is unique in that it is the first to link poor clinical outcomes associated with CCI to the patient's immunophenotypic response to sepsis. However, it is important to note that the criteria we used to define CCI differ from other utilized definitions. Whereas previous definitions heavily relied on the presence of respiratory failure requiring prolonged mechanical ventilation, [34] [35] [36] [37] our definition was more comprehensive in terms of organ dysfunction. We felt the definition for CCI needed incorporate both ICU resource utilization, and a more broad representation of organ dysfunction which includes neurologic, renal, and cardiovascular dysfunction, among others, since non-pulmonary organ dysfunction, such as acute and chronic kidney disease, have been linked to inflammation, immunosuppression, protein catabolism, and poor long-term outcomes. 38 Our definition also incorporates the chronicity of illness associated with previous definitions which is supported by past investigations that found that patients with ICU LOS longer than 14 days demonstrated higher in-patient mortality, greater complication rates, worse discharge dispositions, and early genomic differences of blood leukocytes when compared with those who experienced a more RAP. 24, 25, 39 There are a number of limitations of this study that require acknowledgement and discussion. We enrolled septic patients exclusively from surgical ICUs composed primarily of trauma, emergency general surgery, and noncardiac elective surgery patients. While we suspect the underlying mechanisms of CCI to be similar across critically ill populations, surgical patients are somewhat unique in that their complicated clinical course is characterized by recurrent inflammatory insults which likely the nidus of the persistent dysregulated immune response seen in these patients. Additionally, nonsurgical patients who develop sepsis in the community are generally older with advanced comorbidities, so the incidence of CCI and its underlying phenotype in other septic patient populations will require additional investigation. Second, these studies primarily focused on the patient's in-hospital experience, examining factors that can predict and ultimately define CCI and PICS. While we report inpatient hospital disposition, the long-term outcomes of CCI and PICS remain unclear. We currently are conducting a prospective longitudinal cohort study to assess long-term outcomes (disposition, functional status, physical performance, cognitive ability and 1-year mortality) of these patients (NCT02276417). We conducted this study at a quaternary, academic medical and Level 1 trauma center that has well-established implementation of standardized screening and evidenced-based sepsis management protocols. Whether these results are applicable across the worldwide spectrum of intensive care centers, where sepsis management is more variable, is not known. Finally, in the future, additional analyses, such as functional assays and indirect calorimetry, will be required to supplement the biomarker data and validate PICS in CCI patients.
In conclusion, while inpatient mortality from surgical sepsis continues to decrease, there is a growing proportion of patients that survive to develop the morbid trajectory of CCI. Over half of patients with sepsis in surgical ICUs will develop CCI, and those that do, have discharge dispositions known to be associated with poor long-term outcomes. These patients exhibit biomarker profiles consistent with an immunocatabolic phenotype of persistent inflammation, immune suppression and protein catabolism. Therefore, it is likely that a multimodal therapeutic approach including interventions such as physical therapy, nutritional intervention, and targeted immunotherapy is required to change the trajectory of CCI to one of recovery. AUTHORSHIP J.S., J.M., S.R., T.L., M.S., A.B., A.M., P.E., L.M., F.M., and S.B. contributed to the conception and design of this project. J.S., T.O., Z.W., G.G., B.B., L. M., F.M., and S.B. performed data analysis and interpretation. All authors contributed in drafting the manuscript and/or revising it critically for important intellectual content.
